kiwicub
2021-11-10
[微笑]
Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":847708663,"tweetId":"847708663","gmtCreate":1636551884468,"gmtModify":1636551884553,"author":{"id":4087173810832020,"idStr":"4087173810832020","authorId":4087173810832020,"authorIdStr":"4087173810832020","name":"kiwicub","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[微笑] </span></p></body></html>","htmlText":"<html><head></head><body><p><span>[微笑] </span></p></body></html>","text":"[微笑]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/847708663","repostId":1152344100,"repostType":4,"repost":{"id":"1152344100","kind":"news","pubTimestamp":1636550697,"share":"https://www.laohu8.com/m/news/1152344100?lang=&edition=full","pubTime":"2021-11-10 21:24","market":"us","language":"en","title":"Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill","url":"https://stock-news.laohu8.com/highlight/detail?id=1152344100","media":"Reuters","summary":"Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japane","content":"<p>Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.</p>\n<p>Countries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p>\n<p>Merck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.</p>\n<p>If it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.</p>\n<p>On Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Japan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJapan to pay $1.2 billion for 1.6 mln courses of Merck's COVID-19 pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-10 21:24 GMT+8 <a href=https://finance.yahoo.com/news/1-japan-pay-1-2-131616365.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-japan-pay-1-2-131616365.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/1-japan-pay-1-2-131616365.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152344100","content_text":"Nov 10 (Reuters) - Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday the Japanese government will pay about $1.2 billion for 1.6 million courses of their COVID-19 antiviral pill molnupiravir.\nCountries have rushed to sign deals to buy molnupiravir, since data last month showed that when given early in the illness the drug could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\nMerck expects to make 10 million courses of treatment by the end of 2021, with at least 20 million courses to be produced in 2022.\nIf it gets authorization, molnupiravir, would be the first oral antiviral medication for COVID-19.\nOn Tuesday, the U.S. government said it would buy another $1 billion worth of molnupiravir.","news_type":1},"isVote":1,"tweetType":1,"viewCount":699,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/847708663"}
精彩评论